Abstract
Treatment options for the anemia of chronic kidney disease (CKD) continue to expand. Several hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are undergoing clinical testing and seeking regulatory approval. Erythropoiesis-stimulating agents (ESAs) have been the cornerstone of anemia therapy since 1989, when first-in-class recombinant human erythropoietin was approved. The rise in hemoglobin (Hb) with ESAs demanded greater need for iron and paradoxically greater iron losses due to the higher Hb concentration. This exacerbated iron deficiency led to markedly increased use of intravenous (IV) iron. ESAs, especially at larger dosages aimed to target higher target Hb levels, increase the risk of cardiovascular and thrombotic events, cancer, and death. Prescribed IV iron therapy, while apparently safer, has limited long-term safety evidence and fills iron stores well beyond the normal range, which in part overcomes hepcidin-mediated iron blockade.

This publication has 7 references indexed in Scilit: